ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

10064	Companies
205722	Keywords
135974	Articles
109074	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 07/25/2025 at 08:00, 7 months 29 days ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds
BRIEF

published on 07/24/2025 at 14:45, 7 months 29 days ago

Abivax's $650M Public Offering of ADS

Biotechnology Abivax Capital Increase Public Offering Ads
BRIEF

published on 07/24/2025 at 14:45, 7 months 29 days ago

Abivax lance une offre publique d'ADS de 650 millions de dollars

Biotechnologie Abivax Augmentation De Capital Offre Publique PUBLICITÉS
PRESS RELEASE

published on 07/24/2025 at 14:40, 7 months 29 days ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements thérapeutiques pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Traitements Thérapeutiques Maladies Inflammatoires
PRESS RELEASE

published on 07/24/2025 at 14:40, 7 months 29 days ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares pour financer le développement de thérapies biotechnologiques. Details de l'offre, stabilisation et prévisions financières

Biotechnologie Abivax Ads Offre Publique Modalités Définitives
PRESS RELEASE

published on 07/24/2025 at 14:40, 7 months 29 days ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces the trading resumption of its ordinary shares on Euronext Paris after a temporary halt for a public offering confirmation and pricing announcement

Euronext Paris Abivax Public Offering Clinical-stage Biotechnology Trading Resumption
PRESS RELEASE

published on 07/24/2025 at 14:40, 7 months 29 days ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Négociations Traitements
PRESS RELEASE

published on 07/24/2025 at 14:40, 7 months 29 days ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités de son offre de 650M$ d'American Depositary Shares pour financer des développements cliniques. Stabilisation et options incluses

Abivax Développement Clinique Offre Publique Stabilisation American Depositary Shares
PRESS RELEASE

published on 07/24/2025 at 14:40, 7 months 29 days ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax announces pricing of $650M (€554M) public offering of American Depositary Shares to fund clinical development and working capital, with expected closing on July 28, 2025

Abivax Clinical Development Public Offering Pricing Closing
BRIEF

published on 07/24/2025 at 07:35, 7 months 30 days ago

Abivax suspend temporairement sa cotation sur Euronext Paris

Euronext Paris Biotechnologie Abivax Offre Publique Suspension Des Échanges

Accesswire

Published on 03/23/2026 at 13:05, 8 minutes ago

SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 41 minutes ago

Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 43 minutes ago

Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 12:30, 43 minutes ago

High Tide Resources Announces Closing of Concurrent Non-Brokered Private Placements for Gross Proceeds of $8.3 Million
Published on 03/23/2026 at 12:20, 53 minutes ago

Guanajuato Silver Adds Veteran Mine Operator to Board of Directors

View all ACCESSWIRE

EQS Group

Published on 03/23/2026 at 13:05, 8 minutes ago

Cambrex Advances US and European Expansions
Published on 03/23/2026 at 13:02, 10 minutes ago

Directorate change
Published on 03/23/2026 at 12:40, 33 minutes ago

EQS-Adhoc: Ströer plans a dividend of €1.85 for fiscal year 2025 and approves a share buyback program of up to €50 million
Published on 03/23/2026 at 12:33, 40 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 03/23/2026 at 12:29, 44 minutes ago

Amundi Physical Metals plc: Final Terms

Les Echos

Published on 03/23/2026 at 08:10, 5 hours 3 minutes ago

Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 18 hours ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 18 hours ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 18 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA

View all LES ECHOS COMFI WIRE